<DOC>
	<DOCNO>NCT00761657</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability pharmacodynamic effect 5 different oral dos FG-4592 administer two time three time weekly 4 week subject Chronic Kidney Disease require dialysis .</brief_summary>
	<brief_title>Phase 2 Study FG-4592 Subjects With Anemia Chronic Kidney Disease Not Requiring Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . 18 75 year age . 2 . Chronic Kidney Disease stage 3 4 hemoglobin &lt; 11.0 g/dL 3 . Normal iron study . 4 . Normal folate vitamin B12 level . 5 . Liver function test within normal limit screen . 6 . Absence active chronic rectal bleeding . 7 . Absence diagnosis agerelated macular degeneration ( AMD ) , diabetic macular edema diabetic proliferative retinopathy likely require treatment trial . 8 . Female subject must pregnant breastfeeding . 9 . Male subject partner child must agree use medically acceptable method contraception . 1 . Seropositive HIV . 2 . History chronic liver disease . 3 . History polycystic kidney disease ( PKD ) . 4 . Uncontrolled hypertension ( diastolic BP &gt; 110 mm Hg systolic BP &gt; 170 mm Hg screening ) . 5 . New York Heart Association Class III IV congestive heart failure . 6 . Recent myocardial infarction acute coronary syndrome . 7 . History myelodysplastic syndrome . 8 . Any history malignancy know genetic predisposition develop cancer ( e.g. , diagnostic marker suggest genetic predisposition cancer ) except curatively resect basal cell carcinoma skin , squamous cell carcinoma skin , cervical carcinoma situ , resect benign colonic polyp . 9 . Active inflammatory infection chronic inflammatory disease 10 . Any clinically significant uncontrolled medical condition consider high risk participation investigational study . 11 . Blood clot within 4 week . 12 . History ongoing hemolysis diagnosis hemolytic syndrome . 13 . Known history bone marrow fibrosis . 14 . History hemosiderosis hemochromatosis . 15 . Androgen therapy within 12 week . 16 . Red blood cell transfusion within 12 week . 17 . Therapy erythropoiesis stimulate agent ( ESA ) human recombinant erythropoietin within past 60 day . 18 . Intravenous iron supplementation within past 60 day . 19 . Currently take acetaminophen &gt; 2.6 g/day . 20 . History prior organ transplantation . 21 . Alcohol consumption great 3 drink per day within past year . 22 . Use investigational medication participation investigational study within 4 week precede Day 1 . 23 . Positive urine toxicology screen substance prescribe subject . For subject age 75 year otherwise meet patient selection criterion , subject evaluate casebycase basis include study , per discretion sponsor 's physician representative medical monitor clinical leader .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>CKD</keyword>
	<keyword>Stage 3 4 Chronic Kidney Disease</keyword>
	<keyword>Renal</keyword>
	<keyword>Anemia</keyword>
	<keyword>Oral anemia treatment</keyword>
	<keyword>Hemoglobin level</keyword>
	<keyword>Blood count</keyword>
	<keyword>Erythropoietin</keyword>
</DOC>